dezocine (dalgan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dezocine was discovered and patented by American Home Products Corp. in 1978. Dezocine is a partial opiate drug and was used for pain management under brand name Dalgan. But then usage of this drug was discontinued in US. Dezocine acts as a partial μ-receptor agonist, a κ-receptor antagonist, and a norepinephrine and serotonin reuptake inhibitor (via norepinephrine transporter and serotonin transporter). Dezocine shares the CNS depressant and respiratory depressant effects of opioid analgesics. Dezocine has not been shown to produce clinically significant cardiovascular adverse effects.   NCATS

Chemistry

  • SMILES: C[C@@]12CCCCC[C@@H](CC3=CC=C(O)C=C13)[C@@H]2N
  • InChIKey: VTMVHDZWSFQSQP-VBNZEHGJSA-N
  • Mol. Mass: 245.3599
  • ALogP: 3.11
  • ChEMBL Molecule:
    dezocine  
More Chemistry

Pharmacology

Alternative names

13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecenol | (-)-13beta-amino-5,6,7,8,9,10,11alpha,12-octahydro-5alpha-methyl-5,11-methanobenzocyclodecen-3-ol | 5,11-methanobenzocyclodecen-3-ol, 5,6,7,8,9,10,11,12-octahydro-13-amino-5-methyl- | (-5alpha, 11alpha,13s)-13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-5,11-methanobenzocyclodecen-3-ol | dalgan | dezocina | dezocine | dezocine, (5alpha,11alpha,13s*)-isomer | dezocine hydrobromide | dezocine hydrobromide, (5alpha,11alpha,13*)-isomer | dezocine hydrobromide, (5alpha,11alpha,13s*)-isomer | dezocine hydrobromide, (5r-(5alpha,11alpha,13s*))-isomer | dezocine hydrobromide, (5s-(5alpha,11alpha,13*))-isomer | dezocinum | docozine | wy-16225 | wy-16,225

Organizations (19)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Pain (approved 1989)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Analgesia, Patient-Controlled (Phase 4)

Catheters (Phase 4)

Intubation (Phase 4)

Pain, Postoperative (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue